Investors bet on newer technology and indications for CGTs
As confidence grows for innovative in vivo strategies, some investors are saying they could be the future of the cell…
All articles by Jam Bensilum
Jam Bensilum
Jam Bensilum is a healthcare and pharmaceutical reporter. She has a background in medical communications with extensive experience across both medical affairs and publications. She holds an MSc in Molecular Medicine from Imperial College London and has interests in oncology, infectious disease, biologics, mental health and women’s health.
-
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
Following the creation of the UK’s National Institute for Health and Care Excellence (NICE) in 1999, a cost-effectiveness threshold of…
-
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
Metagenomi will slash a quarter of its workforce and switch up its CEO as part of efforts to extend its…
-
FDA calls for black box warning to be removed from HRT products
The US Food and Drug Administration (FDA) is working with manufacturers to remove black box warnings across hormone replacement therapy (HRT)…
-
FDA halts uniQure’s plans for Huntington’s disease gene therapy
The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and…
-
Alvotech faces FDA setback for its Simponi biosimilar AVT05
Alvotech’s inflammation-targeting biosimilar AVT05 has been rejected by the U.S. Food and Drug Administration (FDA) because of issues with the…
-
Sensei to ditch its lead candidate and cut workforce amidst strategic review
Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider…
-
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a…
-
Excellergy eyes IgE therapy space as Xolair nears patent expiry
After bursting on the scene with a $70m Series A fundraise, Excellergy is forecasting first-in-human trials for both its lead…